Skip to main content
XWEL
NASDAQ Trade & Services

XWELL Pays $2.7M to Buy Out XpresTest Restricted Stock Ahead of $13M Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.85
Mkt Cap
$7.748M
52W Low
$0.255
52W High
$2.2
52W Position info
233% above low
Off High info
61% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

XWEL has more than doubled off its 52-week low of $0.255.

Summary

XWELL repurchased all 279.5 XpresTest restricted stock awards for $2.7 million, paying Chairman Bernstein $1.03M, CEO Ernst $529,875, and CFO Brown $96,341, clearing the subsidiary's cap table before the $13M asset sale.


Key Events · M&A and Partnerships · XWEL

  • XpresTest RSA Repurchase Completed

    XpresTest repurchased 279.5 restricted stock awards for approximately $2.7 million at $9,634.09 per share, with all unvested RSAs becoming fully vested.

  • Insider Payouts Disclosed

    Chairman Bruce Bernstein received $1,030,847.61 for 107 RSAs; CEO Ezra Ernst received $529,874.94 for 55 RSAs; CFO Ian Brown received $96,340.90 for 10 RSAs.

  • Cap Table Simplified for Sale

    No XpresTest RSAs remain outstanding and XWELL now owns 100% of XpresTest, clearing the subsidiary's capitalization ahead of the pending $13 million sale.

  • Sale Proceeds Impact

    Because the $2.7 million was paid early, these amounts will not be deducted from the purchase price payable by the Buyer at closing, preserving the full $13 million sale consideration.


Analysis · XWEL · Trade & Services

XWELL accelerated the repurchase of all outstanding XpresTest restricted stock awards, paying approximately $2.7 million at $9,634.09 per share. Chairman Bruce Bernstein received $1.03 million, CEO Ezra Ernst received $529,875, and CFO Ian Brown received $96,341. This simplifies XpresTest's capitalization ahead of the pending $13 million sale of XpresSpa and XpresTest, and the payments will no longer reduce the purchase price at closing. The early completion with Buyer consent signals the transaction is progressing toward the shareholder vote.

How filings like this one have moved

In the 30 days to Oct 8, 2026, 28.8% of the 1732 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XWEL was trading at $0.85 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $0.26 to $2.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XWEL - Latest Insights

XWEL
Oct 07, 2026, 8:44 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.850
Real-time Price: $0.850 info
Change: $0 (0%) info
Market Cap: $7.748M info
XWEL
Sep 08, 2026, 8:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.9575
Real-time Price: $0.850 info
Change: -$0.1075 (-11%) info
Market Cap: $7.748M info
XWEL
Aug 14, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.980
Real-time Price: $0.850 info
Change: -$0.130 (-13%) info
Market Cap: $7.748M info
XWEL
Aug 05, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.850 info
Change: -$0.190 (-18%) info
Market Cap: $7.748M info
XWEL
Aug 04, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.850 info
Change: -$0.190 (-18%) info
Market Cap: $7.748M info